CLIN NUCL MED 润色咨询

CLINICAL NUCLEAR MEDICINE

出版年份:1976 年文章数:649 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:34.6% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=902336, encodeId=bac2902336c6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床;核医学<br>经验分享:1. 更新下准确的影像因子,杂志官网可查到,2018年为6.709,2019为6.622。<br>2.老牌权威的核医学杂志。<br>3.近几年审稿速度比较快,一般不超过1个月,算审稿速度非常快的杂志了。<br>4.杂志的编辑很nice,但是很严谨。case report,只要图片和病例足够新颖,可以尝试,并不太难。论著有一定难度。<br>5.很临床的杂志,基础的文章不太收。<br>5.很多case report只在CNM发表,所以自引率比别的杂志高点可以理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rQvUN1zHBrywpiakiasoLOFr2w6FAZpJ4k6VRQsprf74lUTXZiavoSUjuLa18Igfbrx8amqbYTJXMVHbVtJOLq3vg/132, createdBy=8bbe1657894, createdName=丹子笑, createdTime=Thu Nov 26 00:17:50 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103324, encodeId=bc4e2103324c3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床研究<br>经验分享:Clin Nucl Med已经上升到和Eur J Nucl Med Mol Imaging、J Nucl Med一个分段的杂志了,但不可否认的是CNM论著的质量和后两者的差距还是比较大的,尤其是和JNM比,不过CNM主打case report,其实也还好了。<br>杂志侧重临床研究,前瞻性和回顾性均可,临床前研究,尤其是动物实验几乎秒拒。CNM文章审稿速度比EJNMMI和JNM慢,不过整体也还行,一审50天左右,修回一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Tue Nov 29 15:58:11 CST 2022, time=2022-11-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=960188, encodeId=d51896018886, content=这杂志20年if对半砍了???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49f25135636, createdName=14665fa9m69暂无昵称, createdTime=Sun Apr 25 08:05:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579239, encodeId=b2e65e9239ca, content=现在自引率这么高了吗<span class="quote">173****0520暂无昵称 2019-10-27 发表::<br>后来知道了吗?</span><span class="quote">173****0520暂无昵称 2019-10-27 00:00:00 发表:<br>后来知道了吗?</span>, beContent=173****0520暂无昵称 2019-10-27 发表:: 后来知道了吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqKeFVU0XGMYxKONpLlkGRwDrQR8jSogU9QicOBk1314ibVzicuYf8jThkRGHHhw2auib6GouZzyS1Lxw/132, createdBy=30ad2388091, createdName=夜以继日的梦想, createdTime=Sat Nov 02 00:00:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578939, encodeId=97355e8939b2, content=后来知道了吗?<span class="quote">lanseyouyu9004 2015-01-18 13:53:00 发表:<br>才四天Decision in Process 什么意思呢</span>, beContent=lanseyouyu9004 2015-01-18 13:53:00 发表: 才四天Decision in Process 什么意思呢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=721b2202035, createdName=120b8a49m20暂无昵称, createdTime=Sun Oct 27 00:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551041, encodeId=3167551041bf, content=没有pet的case也能在这发吗?<span class="quote">leijiang1031_43658003 2017-12-04 发表::<br>SCI(2016):4.563 临床核医学非常权威的杂志</span><span class="quote">leijiang1031_43658003 2017-12-04 09:45:00 发表:<br>临床核医学非常权威的杂志</span>, beContent=leijiang1031_43658003 2017-12-04 发表:: SCI(2016):4.563 临床核医学非常权威的杂志, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949d1402322, createdName=xyxiaochang, createdTime=Tue Jan 09 00:00:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549693, encodeId=238e549693c7, content=临床核医学非常权威的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=372, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75112214477, createdName=leijiang1031_43658003, createdTime=Mon Dec 04 09:45:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545120, encodeId=5a06545120b0, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:核医学领域算是比较老牌的杂志了吧,投Case还是比较容易的,但是CNM的论著还是很难投的;国内很多单位投CNM的case report都投烂了啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160620/IMG5767F7B4941608075.jpg, createdBy=16081612750, createdName=nnnuclear, createdTime=Fri Aug 04 16:55:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526419, encodeId=889752641923, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:1. 临床是其基础,办杂志的宗旨是影响/指导临床,基础研究的文章最好不要投了,99%拒绝。 <br> 2. CaseReport占很大比例,如果figure很impressive,或者是罕见病例,可以投。内容简练为主,不超过500字,临床大夫看的东西就应该精简,赞! <br> 3. 审稿快,一般不会超过一个月。 <br> 4. 楼上某位说错了,彩图第一张500刀,之后每张150刀。 <br> 5. 投四篇中一篇,25%命中率吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0aa1943518, createdName=邵小毛, createdTime=Sun Aug 28 11:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=509212, encodeId=9f5a50921228, content=审稿速度:1.0<br>经验分享:才四天Decision in Process 什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caed1611946, createdName=lanseyouyu9004, createdTime=Sun Jan 18 13:53:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2020-11-26 丹子笑

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:临床;核医学
    经验分享:1. 更新下准确的影像因子,杂志官网可查到,2018年为6.709,2019为6.622。
    2.老牌权威的核医学杂志。
    3.近几年审稿速度比较快,一般不超过1个月,算审稿速度非常快的杂志了。
    4.杂志的编辑很nice,但是很严谨。case report,只要图片和病例足够新颖,可以尝试,并不太难。论著有一定难度。
    5.很临床的杂志,基础的文章不太收。
    5.很多case report只在CNM发表,所以自引率比别的杂志高点可以理解。

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=902336, encodeId=bac2902336c6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床;核医学<br>经验分享:1. 更新下准确的影像因子,杂志官网可查到,2018年为6.709,2019为6.622。<br>2.老牌权威的核医学杂志。<br>3.近几年审稿速度比较快,一般不超过1个月,算审稿速度非常快的杂志了。<br>4.杂志的编辑很nice,但是很严谨。case report,只要图片和病例足够新颖,可以尝试,并不太难。论著有一定难度。<br>5.很临床的杂志,基础的文章不太收。<br>5.很多case report只在CNM发表,所以自引率比别的杂志高点可以理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rQvUN1zHBrywpiakiasoLOFr2w6FAZpJ4k6VRQsprf74lUTXZiavoSUjuLa18Igfbrx8amqbYTJXMVHbVtJOLq3vg/132, createdBy=8bbe1657894, createdName=丹子笑, createdTime=Thu Nov 26 00:17:50 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103324, encodeId=bc4e2103324c3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床研究<br>经验分享:Clin Nucl Med已经上升到和Eur J Nucl Med Mol Imaging、J Nucl Med一个分段的杂志了,但不可否认的是CNM论著的质量和后两者的差距还是比较大的,尤其是和JNM比,不过CNM主打case report,其实也还好了。<br>杂志侧重临床研究,前瞻性和回顾性均可,临床前研究,尤其是动物实验几乎秒拒。CNM文章审稿速度比EJNMMI和JNM慢,不过整体也还行,一审50天左右,修回一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Tue Nov 29 15:58:11 CST 2022, time=2022-11-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=960188, encodeId=d51896018886, content=这杂志20年if对半砍了???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49f25135636, createdName=14665fa9m69暂无昵称, createdTime=Sun Apr 25 08:05:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579239, encodeId=b2e65e9239ca, content=现在自引率这么高了吗<span class="quote">173****0520暂无昵称 2019-10-27 发表::<br>后来知道了吗?</span><span class="quote">173****0520暂无昵称 2019-10-27 00:00:00 发表:<br>后来知道了吗?</span>, beContent=173****0520暂无昵称 2019-10-27 发表:: 后来知道了吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqKeFVU0XGMYxKONpLlkGRwDrQR8jSogU9QicOBk1314ibVzicuYf8jThkRGHHhw2auib6GouZzyS1Lxw/132, createdBy=30ad2388091, createdName=夜以继日的梦想, createdTime=Sat Nov 02 00:00:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578939, encodeId=97355e8939b2, content=后来知道了吗?<span class="quote">lanseyouyu9004 2015-01-18 13:53:00 发表:<br>才四天Decision in Process 什么意思呢</span>, beContent=lanseyouyu9004 2015-01-18 13:53:00 发表: 才四天Decision in Process 什么意思呢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=721b2202035, createdName=120b8a49m20暂无昵称, createdTime=Sun Oct 27 00:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551041, encodeId=3167551041bf, content=没有pet的case也能在这发吗?<span class="quote">leijiang1031_43658003 2017-12-04 发表::<br>SCI(2016):4.563 临床核医学非常权威的杂志</span><span class="quote">leijiang1031_43658003 2017-12-04 09:45:00 发表:<br>临床核医学非常权威的杂志</span>, beContent=leijiang1031_43658003 2017-12-04 发表:: SCI(2016):4.563 临床核医学非常权威的杂志, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949d1402322, createdName=xyxiaochang, createdTime=Tue Jan 09 00:00:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549693, encodeId=238e549693c7, content=临床核医学非常权威的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=372, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75112214477, createdName=leijiang1031_43658003, createdTime=Mon Dec 04 09:45:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545120, encodeId=5a06545120b0, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:核医学领域算是比较老牌的杂志了吧,投Case还是比较容易的,但是CNM的论著还是很难投的;国内很多单位投CNM的case report都投烂了啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160620/IMG5767F7B4941608075.jpg, createdBy=16081612750, createdName=nnnuclear, createdTime=Fri Aug 04 16:55:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526419, encodeId=889752641923, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:1. 临床是其基础,办杂志的宗旨是影响/指导临床,基础研究的文章最好不要投了,99%拒绝。 <br> 2. CaseReport占很大比例,如果figure很impressive,或者是罕见病例,可以投。内容简练为主,不超过500字,临床大夫看的东西就应该精简,赞! <br> 3. 审稿快,一般不会超过一个月。 <br> 4. 楼上某位说错了,彩图第一张500刀,之后每张150刀。 <br> 5. 投四篇中一篇,25%命中率吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0aa1943518, createdName=邵小毛, createdTime=Sun Aug 28 11:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=509212, encodeId=9f5a50921228, content=审稿速度:1.0<br>经验分享:才四天Decision in Process 什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caed1611946, createdName=lanseyouyu9004, createdTime=Sun Jan 18 13:53:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2022-11-29 我又不乱来 来自北京

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:临床研究
    经验分享:Clin Nucl Med已经上升到和Eur J Nucl Med Mol Imaging、J Nucl Med一个分段的杂志了,但不可否认的是CNM论著的质量和后两者的差距还是比较大的,尤其是和JNM比,不过CNM主打case report,其实也还好了。
    杂志侧重临床研究,前瞻性和回顾性均可,临床前研究,尤其是动物实验几乎秒拒。CNM文章审稿速度比EJNMMI和JNM慢,不过整体也还行,一审50天左右,修回一个月。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=902336, encodeId=bac2902336c6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床;核医学<br>经验分享:1. 更新下准确的影像因子,杂志官网可查到,2018年为6.709,2019为6.622。<br>2.老牌权威的核医学杂志。<br>3.近几年审稿速度比较快,一般不超过1个月,算审稿速度非常快的杂志了。<br>4.杂志的编辑很nice,但是很严谨。case report,只要图片和病例足够新颖,可以尝试,并不太难。论著有一定难度。<br>5.很临床的杂志,基础的文章不太收。<br>5.很多case report只在CNM发表,所以自引率比别的杂志高点可以理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rQvUN1zHBrywpiakiasoLOFr2w6FAZpJ4k6VRQsprf74lUTXZiavoSUjuLa18Igfbrx8amqbYTJXMVHbVtJOLq3vg/132, createdBy=8bbe1657894, createdName=丹子笑, createdTime=Thu Nov 26 00:17:50 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103324, encodeId=bc4e2103324c3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床研究<br>经验分享:Clin Nucl Med已经上升到和Eur J Nucl Med Mol Imaging、J Nucl Med一个分段的杂志了,但不可否认的是CNM论著的质量和后两者的差距还是比较大的,尤其是和JNM比,不过CNM主打case report,其实也还好了。<br>杂志侧重临床研究,前瞻性和回顾性均可,临床前研究,尤其是动物实验几乎秒拒。CNM文章审稿速度比EJNMMI和JNM慢,不过整体也还行,一审50天左右,修回一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Tue Nov 29 15:58:11 CST 2022, time=2022-11-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=960188, encodeId=d51896018886, content=这杂志20年if对半砍了???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49f25135636, createdName=14665fa9m69暂无昵称, createdTime=Sun Apr 25 08:05:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579239, encodeId=b2e65e9239ca, content=现在自引率这么高了吗<span class="quote">173****0520暂无昵称 2019-10-27 发表::<br>后来知道了吗?</span><span class="quote">173****0520暂无昵称 2019-10-27 00:00:00 发表:<br>后来知道了吗?</span>, beContent=173****0520暂无昵称 2019-10-27 发表:: 后来知道了吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqKeFVU0XGMYxKONpLlkGRwDrQR8jSogU9QicOBk1314ibVzicuYf8jThkRGHHhw2auib6GouZzyS1Lxw/132, createdBy=30ad2388091, createdName=夜以继日的梦想, createdTime=Sat Nov 02 00:00:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578939, encodeId=97355e8939b2, content=后来知道了吗?<span class="quote">lanseyouyu9004 2015-01-18 13:53:00 发表:<br>才四天Decision in Process 什么意思呢</span>, beContent=lanseyouyu9004 2015-01-18 13:53:00 发表: 才四天Decision in Process 什么意思呢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=721b2202035, createdName=120b8a49m20暂无昵称, createdTime=Sun Oct 27 00:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551041, encodeId=3167551041bf, content=没有pet的case也能在这发吗?<span class="quote">leijiang1031_43658003 2017-12-04 发表::<br>SCI(2016):4.563 临床核医学非常权威的杂志</span><span class="quote">leijiang1031_43658003 2017-12-04 09:45:00 发表:<br>临床核医学非常权威的杂志</span>, beContent=leijiang1031_43658003 2017-12-04 发表:: SCI(2016):4.563 临床核医学非常权威的杂志, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949d1402322, createdName=xyxiaochang, createdTime=Tue Jan 09 00:00:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549693, encodeId=238e549693c7, content=临床核医学非常权威的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=372, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75112214477, createdName=leijiang1031_43658003, createdTime=Mon Dec 04 09:45:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545120, encodeId=5a06545120b0, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:核医学领域算是比较老牌的杂志了吧,投Case还是比较容易的,但是CNM的论著还是很难投的;国内很多单位投CNM的case report都投烂了啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160620/IMG5767F7B4941608075.jpg, createdBy=16081612750, createdName=nnnuclear, createdTime=Fri Aug 04 16:55:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526419, encodeId=889752641923, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:1. 临床是其基础,办杂志的宗旨是影响/指导临床,基础研究的文章最好不要投了,99%拒绝。 <br> 2. CaseReport占很大比例,如果figure很impressive,或者是罕见病例,可以投。内容简练为主,不超过500字,临床大夫看的东西就应该精简,赞! <br> 3. 审稿快,一般不会超过一个月。 <br> 4. 楼上某位说错了,彩图第一张500刀,之后每张150刀。 <br> 5. 投四篇中一篇,25%命中率吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0aa1943518, createdName=邵小毛, createdTime=Sun Aug 28 11:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=509212, encodeId=9f5a50921228, content=审稿速度:1.0<br>经验分享:才四天Decision in Process 什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caed1611946, createdName=lanseyouyu9004, createdTime=Sun Jan 18 13:53:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2021-04-25 14665fa9m69暂无昵称

    这杂志20年if对半砍了???

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=902336, encodeId=bac2902336c6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床;核医学<br>经验分享:1. 更新下准确的影像因子,杂志官网可查到,2018年为6.709,2019为6.622。<br>2.老牌权威的核医学杂志。<br>3.近几年审稿速度比较快,一般不超过1个月,算审稿速度非常快的杂志了。<br>4.杂志的编辑很nice,但是很严谨。case report,只要图片和病例足够新颖,可以尝试,并不太难。论著有一定难度。<br>5.很临床的杂志,基础的文章不太收。<br>5.很多case report只在CNM发表,所以自引率比别的杂志高点可以理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rQvUN1zHBrywpiakiasoLOFr2w6FAZpJ4k6VRQsprf74lUTXZiavoSUjuLa18Igfbrx8amqbYTJXMVHbVtJOLq3vg/132, createdBy=8bbe1657894, createdName=丹子笑, createdTime=Thu Nov 26 00:17:50 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103324, encodeId=bc4e2103324c3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床研究<br>经验分享:Clin Nucl Med已经上升到和Eur J Nucl Med Mol Imaging、J Nucl Med一个分段的杂志了,但不可否认的是CNM论著的质量和后两者的差距还是比较大的,尤其是和JNM比,不过CNM主打case report,其实也还好了。<br>杂志侧重临床研究,前瞻性和回顾性均可,临床前研究,尤其是动物实验几乎秒拒。CNM文章审稿速度比EJNMMI和JNM慢,不过整体也还行,一审50天左右,修回一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Tue Nov 29 15:58:11 CST 2022, time=2022-11-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=960188, encodeId=d51896018886, content=这杂志20年if对半砍了???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49f25135636, createdName=14665fa9m69暂无昵称, createdTime=Sun Apr 25 08:05:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579239, encodeId=b2e65e9239ca, content=现在自引率这么高了吗<span class="quote">173****0520暂无昵称 2019-10-27 发表::<br>后来知道了吗?</span><span class="quote">173****0520暂无昵称 2019-10-27 00:00:00 发表:<br>后来知道了吗?</span>, beContent=173****0520暂无昵称 2019-10-27 发表:: 后来知道了吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqKeFVU0XGMYxKONpLlkGRwDrQR8jSogU9QicOBk1314ibVzicuYf8jThkRGHHhw2auib6GouZzyS1Lxw/132, createdBy=30ad2388091, createdName=夜以继日的梦想, createdTime=Sat Nov 02 00:00:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578939, encodeId=97355e8939b2, content=后来知道了吗?<span class="quote">lanseyouyu9004 2015-01-18 13:53:00 发表:<br>才四天Decision in Process 什么意思呢</span>, beContent=lanseyouyu9004 2015-01-18 13:53:00 发表: 才四天Decision in Process 什么意思呢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=721b2202035, createdName=120b8a49m20暂无昵称, createdTime=Sun Oct 27 00:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551041, encodeId=3167551041bf, content=没有pet的case也能在这发吗?<span class="quote">leijiang1031_43658003 2017-12-04 发表::<br>SCI(2016):4.563 临床核医学非常权威的杂志</span><span class="quote">leijiang1031_43658003 2017-12-04 09:45:00 发表:<br>临床核医学非常权威的杂志</span>, beContent=leijiang1031_43658003 2017-12-04 发表:: SCI(2016):4.563 临床核医学非常权威的杂志, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949d1402322, createdName=xyxiaochang, createdTime=Tue Jan 09 00:00:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549693, encodeId=238e549693c7, content=临床核医学非常权威的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=372, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75112214477, createdName=leijiang1031_43658003, createdTime=Mon Dec 04 09:45:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545120, encodeId=5a06545120b0, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:核医学领域算是比较老牌的杂志了吧,投Case还是比较容易的,但是CNM的论著还是很难投的;国内很多单位投CNM的case report都投烂了啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160620/IMG5767F7B4941608075.jpg, createdBy=16081612750, createdName=nnnuclear, createdTime=Fri Aug 04 16:55:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526419, encodeId=889752641923, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:1. 临床是其基础,办杂志的宗旨是影响/指导临床,基础研究的文章最好不要投了,99%拒绝。 <br> 2. CaseReport占很大比例,如果figure很impressive,或者是罕见病例,可以投。内容简练为主,不超过500字,临床大夫看的东西就应该精简,赞! <br> 3. 审稿快,一般不会超过一个月。 <br> 4. 楼上某位说错了,彩图第一张500刀,之后每张150刀。 <br> 5. 投四篇中一篇,25%命中率吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0aa1943518, createdName=邵小毛, createdTime=Sun Aug 28 11:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=509212, encodeId=9f5a50921228, content=审稿速度:1.0<br>经验分享:才四天Decision in Process 什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caed1611946, createdName=lanseyouyu9004, createdTime=Sun Jan 18 13:53:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2019-11-02 夜以继日的梦想

    现在自引率这么高了吗173****0520暂无昵称 2019-10-27 发表::
    后来知道了吗?
    173****0520暂无昵称 2019-10-27 00:00:00 发表:
    后来知道了吗?

    173****0520暂无昵称 2019-10-27 发表:: 后来知道了吗?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=902336, encodeId=bac2902336c6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床;核医学<br>经验分享:1. 更新下准确的影像因子,杂志官网可查到,2018年为6.709,2019为6.622。<br>2.老牌权威的核医学杂志。<br>3.近几年审稿速度比较快,一般不超过1个月,算审稿速度非常快的杂志了。<br>4.杂志的编辑很nice,但是很严谨。case report,只要图片和病例足够新颖,可以尝试,并不太难。论著有一定难度。<br>5.很临床的杂志,基础的文章不太收。<br>5.很多case report只在CNM发表,所以自引率比别的杂志高点可以理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rQvUN1zHBrywpiakiasoLOFr2w6FAZpJ4k6VRQsprf74lUTXZiavoSUjuLa18Igfbrx8amqbYTJXMVHbVtJOLq3vg/132, createdBy=8bbe1657894, createdName=丹子笑, createdTime=Thu Nov 26 00:17:50 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103324, encodeId=bc4e2103324c3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床研究<br>经验分享:Clin Nucl Med已经上升到和Eur J Nucl Med Mol Imaging、J Nucl Med一个分段的杂志了,但不可否认的是CNM论著的质量和后两者的差距还是比较大的,尤其是和JNM比,不过CNM主打case report,其实也还好了。<br>杂志侧重临床研究,前瞻性和回顾性均可,临床前研究,尤其是动物实验几乎秒拒。CNM文章审稿速度比EJNMMI和JNM慢,不过整体也还行,一审50天左右,修回一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Tue Nov 29 15:58:11 CST 2022, time=2022-11-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=960188, encodeId=d51896018886, content=这杂志20年if对半砍了???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49f25135636, createdName=14665fa9m69暂无昵称, createdTime=Sun Apr 25 08:05:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579239, encodeId=b2e65e9239ca, content=现在自引率这么高了吗<span class="quote">173****0520暂无昵称 2019-10-27 发表::<br>后来知道了吗?</span><span class="quote">173****0520暂无昵称 2019-10-27 00:00:00 发表:<br>后来知道了吗?</span>, beContent=173****0520暂无昵称 2019-10-27 发表:: 后来知道了吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqKeFVU0XGMYxKONpLlkGRwDrQR8jSogU9QicOBk1314ibVzicuYf8jThkRGHHhw2auib6GouZzyS1Lxw/132, createdBy=30ad2388091, createdName=夜以继日的梦想, createdTime=Sat Nov 02 00:00:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578939, encodeId=97355e8939b2, content=后来知道了吗?<span class="quote">lanseyouyu9004 2015-01-18 13:53:00 发表:<br>才四天Decision in Process 什么意思呢</span>, beContent=lanseyouyu9004 2015-01-18 13:53:00 发表: 才四天Decision in Process 什么意思呢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=721b2202035, createdName=120b8a49m20暂无昵称, createdTime=Sun Oct 27 00:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551041, encodeId=3167551041bf, content=没有pet的case也能在这发吗?<span class="quote">leijiang1031_43658003 2017-12-04 发表::<br>SCI(2016):4.563 临床核医学非常权威的杂志</span><span class="quote">leijiang1031_43658003 2017-12-04 09:45:00 发表:<br>临床核医学非常权威的杂志</span>, beContent=leijiang1031_43658003 2017-12-04 发表:: SCI(2016):4.563 临床核医学非常权威的杂志, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949d1402322, createdName=xyxiaochang, createdTime=Tue Jan 09 00:00:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549693, encodeId=238e549693c7, content=临床核医学非常权威的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=372, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75112214477, createdName=leijiang1031_43658003, createdTime=Mon Dec 04 09:45:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545120, encodeId=5a06545120b0, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:核医学领域算是比较老牌的杂志了吧,投Case还是比较容易的,但是CNM的论著还是很难投的;国内很多单位投CNM的case report都投烂了啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160620/IMG5767F7B4941608075.jpg, createdBy=16081612750, createdName=nnnuclear, createdTime=Fri Aug 04 16:55:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526419, encodeId=889752641923, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:1. 临床是其基础,办杂志的宗旨是影响/指导临床,基础研究的文章最好不要投了,99%拒绝。 <br> 2. CaseReport占很大比例,如果figure很impressive,或者是罕见病例,可以投。内容简练为主,不超过500字,临床大夫看的东西就应该精简,赞! <br> 3. 审稿快,一般不会超过一个月。 <br> 4. 楼上某位说错了,彩图第一张500刀,之后每张150刀。 <br> 5. 投四篇中一篇,25%命中率吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0aa1943518, createdName=邵小毛, createdTime=Sun Aug 28 11:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=509212, encodeId=9f5a50921228, content=审稿速度:1.0<br>经验分享:才四天Decision in Process 什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caed1611946, createdName=lanseyouyu9004, createdTime=Sun Jan 18 13:53:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2019-10-27 120b8a49m20暂无昵称

    后来知道了吗?lanseyouyu9004 2015-01-18 13:53:00 发表:
    才四天Decision in Process 什么意思呢

    lanseyouyu9004 2015-01-18 13:53:00 发表: 才四天Decision in Process 什么意思呢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=902336, encodeId=bac2902336c6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床;核医学<br>经验分享:1. 更新下准确的影像因子,杂志官网可查到,2018年为6.709,2019为6.622。<br>2.老牌权威的核医学杂志。<br>3.近几年审稿速度比较快,一般不超过1个月,算审稿速度非常快的杂志了。<br>4.杂志的编辑很nice,但是很严谨。case report,只要图片和病例足够新颖,可以尝试,并不太难。论著有一定难度。<br>5.很临床的杂志,基础的文章不太收。<br>5.很多case report只在CNM发表,所以自引率比别的杂志高点可以理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rQvUN1zHBrywpiakiasoLOFr2w6FAZpJ4k6VRQsprf74lUTXZiavoSUjuLa18Igfbrx8amqbYTJXMVHbVtJOLq3vg/132, createdBy=8bbe1657894, createdName=丹子笑, createdTime=Thu Nov 26 00:17:50 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103324, encodeId=bc4e2103324c3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床研究<br>经验分享:Clin Nucl Med已经上升到和Eur J Nucl Med Mol Imaging、J Nucl Med一个分段的杂志了,但不可否认的是CNM论著的质量和后两者的差距还是比较大的,尤其是和JNM比,不过CNM主打case report,其实也还好了。<br>杂志侧重临床研究,前瞻性和回顾性均可,临床前研究,尤其是动物实验几乎秒拒。CNM文章审稿速度比EJNMMI和JNM慢,不过整体也还行,一审50天左右,修回一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Tue Nov 29 15:58:11 CST 2022, time=2022-11-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=960188, encodeId=d51896018886, content=这杂志20年if对半砍了???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49f25135636, createdName=14665fa9m69暂无昵称, createdTime=Sun Apr 25 08:05:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579239, encodeId=b2e65e9239ca, content=现在自引率这么高了吗<span class="quote">173****0520暂无昵称 2019-10-27 发表::<br>后来知道了吗?</span><span class="quote">173****0520暂无昵称 2019-10-27 00:00:00 发表:<br>后来知道了吗?</span>, beContent=173****0520暂无昵称 2019-10-27 发表:: 后来知道了吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqKeFVU0XGMYxKONpLlkGRwDrQR8jSogU9QicOBk1314ibVzicuYf8jThkRGHHhw2auib6GouZzyS1Lxw/132, createdBy=30ad2388091, createdName=夜以继日的梦想, createdTime=Sat Nov 02 00:00:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578939, encodeId=97355e8939b2, content=后来知道了吗?<span class="quote">lanseyouyu9004 2015-01-18 13:53:00 发表:<br>才四天Decision in Process 什么意思呢</span>, beContent=lanseyouyu9004 2015-01-18 13:53:00 发表: 才四天Decision in Process 什么意思呢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=721b2202035, createdName=120b8a49m20暂无昵称, createdTime=Sun Oct 27 00:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551041, encodeId=3167551041bf, content=没有pet的case也能在这发吗?<span class="quote">leijiang1031_43658003 2017-12-04 发表::<br>SCI(2016):4.563 临床核医学非常权威的杂志</span><span class="quote">leijiang1031_43658003 2017-12-04 09:45:00 发表:<br>临床核医学非常权威的杂志</span>, beContent=leijiang1031_43658003 2017-12-04 发表:: SCI(2016):4.563 临床核医学非常权威的杂志, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949d1402322, createdName=xyxiaochang, createdTime=Tue Jan 09 00:00:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549693, encodeId=238e549693c7, content=临床核医学非常权威的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=372, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75112214477, createdName=leijiang1031_43658003, createdTime=Mon Dec 04 09:45:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545120, encodeId=5a06545120b0, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:核医学领域算是比较老牌的杂志了吧,投Case还是比较容易的,但是CNM的论著还是很难投的;国内很多单位投CNM的case report都投烂了啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160620/IMG5767F7B4941608075.jpg, createdBy=16081612750, createdName=nnnuclear, createdTime=Fri Aug 04 16:55:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526419, encodeId=889752641923, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:1. 临床是其基础,办杂志的宗旨是影响/指导临床,基础研究的文章最好不要投了,99%拒绝。 <br> 2. CaseReport占很大比例,如果figure很impressive,或者是罕见病例,可以投。内容简练为主,不超过500字,临床大夫看的东西就应该精简,赞! <br> 3. 审稿快,一般不会超过一个月。 <br> 4. 楼上某位说错了,彩图第一张500刀,之后每张150刀。 <br> 5. 投四篇中一篇,25%命中率吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0aa1943518, createdName=邵小毛, createdTime=Sun Aug 28 11:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=509212, encodeId=9f5a50921228, content=审稿速度:1.0<br>经验分享:才四天Decision in Process 什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caed1611946, createdName=lanseyouyu9004, createdTime=Sun Jan 18 13:53:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2018-01-09 xyxiaochang

    没有pet的case也能在这发吗?leijiang1031_43658003 2017-12-04 发表::
    SCI(2016):4.563 临床核医学非常权威的杂志
    leijiang1031_43658003 2017-12-04 09:45:00 发表:
    临床核医学非常权威的杂志

    leijiang1031_43658003 2017-12-04 发表:: SCI(2016):4.563 临床核医学非常权威的杂志

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=902336, encodeId=bac2902336c6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床;核医学<br>经验分享:1. 更新下准确的影像因子,杂志官网可查到,2018年为6.709,2019为6.622。<br>2.老牌权威的核医学杂志。<br>3.近几年审稿速度比较快,一般不超过1个月,算审稿速度非常快的杂志了。<br>4.杂志的编辑很nice,但是很严谨。case report,只要图片和病例足够新颖,可以尝试,并不太难。论著有一定难度。<br>5.很临床的杂志,基础的文章不太收。<br>5.很多case report只在CNM发表,所以自引率比别的杂志高点可以理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rQvUN1zHBrywpiakiasoLOFr2w6FAZpJ4k6VRQsprf74lUTXZiavoSUjuLa18Igfbrx8amqbYTJXMVHbVtJOLq3vg/132, createdBy=8bbe1657894, createdName=丹子笑, createdTime=Thu Nov 26 00:17:50 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103324, encodeId=bc4e2103324c3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床研究<br>经验分享:Clin Nucl Med已经上升到和Eur J Nucl Med Mol Imaging、J Nucl Med一个分段的杂志了,但不可否认的是CNM论著的质量和后两者的差距还是比较大的,尤其是和JNM比,不过CNM主打case report,其实也还好了。<br>杂志侧重临床研究,前瞻性和回顾性均可,临床前研究,尤其是动物实验几乎秒拒。CNM文章审稿速度比EJNMMI和JNM慢,不过整体也还行,一审50天左右,修回一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Tue Nov 29 15:58:11 CST 2022, time=2022-11-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=960188, encodeId=d51896018886, content=这杂志20年if对半砍了???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49f25135636, createdName=14665fa9m69暂无昵称, createdTime=Sun Apr 25 08:05:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579239, encodeId=b2e65e9239ca, content=现在自引率这么高了吗<span class="quote">173****0520暂无昵称 2019-10-27 发表::<br>后来知道了吗?</span><span class="quote">173****0520暂无昵称 2019-10-27 00:00:00 发表:<br>后来知道了吗?</span>, beContent=173****0520暂无昵称 2019-10-27 发表:: 后来知道了吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqKeFVU0XGMYxKONpLlkGRwDrQR8jSogU9QicOBk1314ibVzicuYf8jThkRGHHhw2auib6GouZzyS1Lxw/132, createdBy=30ad2388091, createdName=夜以继日的梦想, createdTime=Sat Nov 02 00:00:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578939, encodeId=97355e8939b2, content=后来知道了吗?<span class="quote">lanseyouyu9004 2015-01-18 13:53:00 发表:<br>才四天Decision in Process 什么意思呢</span>, beContent=lanseyouyu9004 2015-01-18 13:53:00 发表: 才四天Decision in Process 什么意思呢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=721b2202035, createdName=120b8a49m20暂无昵称, createdTime=Sun Oct 27 00:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551041, encodeId=3167551041bf, content=没有pet的case也能在这发吗?<span class="quote">leijiang1031_43658003 2017-12-04 发表::<br>SCI(2016):4.563 临床核医学非常权威的杂志</span><span class="quote">leijiang1031_43658003 2017-12-04 09:45:00 发表:<br>临床核医学非常权威的杂志</span>, beContent=leijiang1031_43658003 2017-12-04 发表:: SCI(2016):4.563 临床核医学非常权威的杂志, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949d1402322, createdName=xyxiaochang, createdTime=Tue Jan 09 00:00:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549693, encodeId=238e549693c7, content=临床核医学非常权威的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=372, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75112214477, createdName=leijiang1031_43658003, createdTime=Mon Dec 04 09:45:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545120, encodeId=5a06545120b0, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:核医学领域算是比较老牌的杂志了吧,投Case还是比较容易的,但是CNM的论著还是很难投的;国内很多单位投CNM的case report都投烂了啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160620/IMG5767F7B4941608075.jpg, createdBy=16081612750, createdName=nnnuclear, createdTime=Fri Aug 04 16:55:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526419, encodeId=889752641923, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:1. 临床是其基础,办杂志的宗旨是影响/指导临床,基础研究的文章最好不要投了,99%拒绝。 <br> 2. CaseReport占很大比例,如果figure很impressive,或者是罕见病例,可以投。内容简练为主,不超过500字,临床大夫看的东西就应该精简,赞! <br> 3. 审稿快,一般不会超过一个月。 <br> 4. 楼上某位说错了,彩图第一张500刀,之后每张150刀。 <br> 5. 投四篇中一篇,25%命中率吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0aa1943518, createdName=邵小毛, createdTime=Sun Aug 28 11:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=509212, encodeId=9f5a50921228, content=审稿速度:1.0<br>经验分享:才四天Decision in Process 什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caed1611946, createdName=lanseyouyu9004, createdTime=Sun Jan 18 13:53:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2017-12-04 leijiang1031_43658003

    临床核医学非常权威的杂志

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=902336, encodeId=bac2902336c6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床;核医学<br>经验分享:1. 更新下准确的影像因子,杂志官网可查到,2018年为6.709,2019为6.622。<br>2.老牌权威的核医学杂志。<br>3.近几年审稿速度比较快,一般不超过1个月,算审稿速度非常快的杂志了。<br>4.杂志的编辑很nice,但是很严谨。case report,只要图片和病例足够新颖,可以尝试,并不太难。论著有一定难度。<br>5.很临床的杂志,基础的文章不太收。<br>5.很多case report只在CNM发表,所以自引率比别的杂志高点可以理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rQvUN1zHBrywpiakiasoLOFr2w6FAZpJ4k6VRQsprf74lUTXZiavoSUjuLa18Igfbrx8amqbYTJXMVHbVtJOLq3vg/132, createdBy=8bbe1657894, createdName=丹子笑, createdTime=Thu Nov 26 00:17:50 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103324, encodeId=bc4e2103324c3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床研究<br>经验分享:Clin Nucl Med已经上升到和Eur J Nucl Med Mol Imaging、J Nucl Med一个分段的杂志了,但不可否认的是CNM论著的质量和后两者的差距还是比较大的,尤其是和JNM比,不过CNM主打case report,其实也还好了。<br>杂志侧重临床研究,前瞻性和回顾性均可,临床前研究,尤其是动物实验几乎秒拒。CNM文章审稿速度比EJNMMI和JNM慢,不过整体也还行,一审50天左右,修回一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Tue Nov 29 15:58:11 CST 2022, time=2022-11-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=960188, encodeId=d51896018886, content=这杂志20年if对半砍了???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49f25135636, createdName=14665fa9m69暂无昵称, createdTime=Sun Apr 25 08:05:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579239, encodeId=b2e65e9239ca, content=现在自引率这么高了吗<span class="quote">173****0520暂无昵称 2019-10-27 发表::<br>后来知道了吗?</span><span class="quote">173****0520暂无昵称 2019-10-27 00:00:00 发表:<br>后来知道了吗?</span>, beContent=173****0520暂无昵称 2019-10-27 发表:: 后来知道了吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqKeFVU0XGMYxKONpLlkGRwDrQR8jSogU9QicOBk1314ibVzicuYf8jThkRGHHhw2auib6GouZzyS1Lxw/132, createdBy=30ad2388091, createdName=夜以继日的梦想, createdTime=Sat Nov 02 00:00:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578939, encodeId=97355e8939b2, content=后来知道了吗?<span class="quote">lanseyouyu9004 2015-01-18 13:53:00 发表:<br>才四天Decision in Process 什么意思呢</span>, beContent=lanseyouyu9004 2015-01-18 13:53:00 发表: 才四天Decision in Process 什么意思呢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=721b2202035, createdName=120b8a49m20暂无昵称, createdTime=Sun Oct 27 00:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551041, encodeId=3167551041bf, content=没有pet的case也能在这发吗?<span class="quote">leijiang1031_43658003 2017-12-04 发表::<br>SCI(2016):4.563 临床核医学非常权威的杂志</span><span class="quote">leijiang1031_43658003 2017-12-04 09:45:00 发表:<br>临床核医学非常权威的杂志</span>, beContent=leijiang1031_43658003 2017-12-04 发表:: SCI(2016):4.563 临床核医学非常权威的杂志, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949d1402322, createdName=xyxiaochang, createdTime=Tue Jan 09 00:00:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549693, encodeId=238e549693c7, content=临床核医学非常权威的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=372, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75112214477, createdName=leijiang1031_43658003, createdTime=Mon Dec 04 09:45:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545120, encodeId=5a06545120b0, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:核医学领域算是比较老牌的杂志了吧,投Case还是比较容易的,但是CNM的论著还是很难投的;国内很多单位投CNM的case report都投烂了啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160620/IMG5767F7B4941608075.jpg, createdBy=16081612750, createdName=nnnuclear, createdTime=Fri Aug 04 16:55:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526419, encodeId=889752641923, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:1. 临床是其基础,办杂志的宗旨是影响/指导临床,基础研究的文章最好不要投了,99%拒绝。 <br> 2. CaseReport占很大比例,如果figure很impressive,或者是罕见病例,可以投。内容简练为主,不超过500字,临床大夫看的东西就应该精简,赞! <br> 3. 审稿快,一般不会超过一个月。 <br> 4. 楼上某位说错了,彩图第一张500刀,之后每张150刀。 <br> 5. 投四篇中一篇,25%命中率吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0aa1943518, createdName=邵小毛, createdTime=Sun Aug 28 11:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=509212, encodeId=9f5a50921228, content=审稿速度:1.0<br>经验分享:才四天Decision in Process 什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caed1611946, createdName=lanseyouyu9004, createdTime=Sun Jan 18 13:53:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2017-08-04 nnnuclear

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:核医学领域算是比较老牌的杂志了吧,投Case还是比较容易的,但是CNM的论著还是很难投的;国内很多单位投CNM的case report都投烂了啊。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=902336, encodeId=bac2902336c6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床;核医学<br>经验分享:1. 更新下准确的影像因子,杂志官网可查到,2018年为6.709,2019为6.622。<br>2.老牌权威的核医学杂志。<br>3.近几年审稿速度比较快,一般不超过1个月,算审稿速度非常快的杂志了。<br>4.杂志的编辑很nice,但是很严谨。case report,只要图片和病例足够新颖,可以尝试,并不太难。论著有一定难度。<br>5.很临床的杂志,基础的文章不太收。<br>5.很多case report只在CNM发表,所以自引率比别的杂志高点可以理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rQvUN1zHBrywpiakiasoLOFr2w6FAZpJ4k6VRQsprf74lUTXZiavoSUjuLa18Igfbrx8amqbYTJXMVHbVtJOLq3vg/132, createdBy=8bbe1657894, createdName=丹子笑, createdTime=Thu Nov 26 00:17:50 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103324, encodeId=bc4e2103324c3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床研究<br>经验分享:Clin Nucl Med已经上升到和Eur J Nucl Med Mol Imaging、J Nucl Med一个分段的杂志了,但不可否认的是CNM论著的质量和后两者的差距还是比较大的,尤其是和JNM比,不过CNM主打case report,其实也还好了。<br>杂志侧重临床研究,前瞻性和回顾性均可,临床前研究,尤其是动物实验几乎秒拒。CNM文章审稿速度比EJNMMI和JNM慢,不过整体也还行,一审50天左右,修回一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Tue Nov 29 15:58:11 CST 2022, time=2022-11-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=960188, encodeId=d51896018886, content=这杂志20年if对半砍了???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49f25135636, createdName=14665fa9m69暂无昵称, createdTime=Sun Apr 25 08:05:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579239, encodeId=b2e65e9239ca, content=现在自引率这么高了吗<span class="quote">173****0520暂无昵称 2019-10-27 发表::<br>后来知道了吗?</span><span class="quote">173****0520暂无昵称 2019-10-27 00:00:00 发表:<br>后来知道了吗?</span>, beContent=173****0520暂无昵称 2019-10-27 发表:: 后来知道了吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqKeFVU0XGMYxKONpLlkGRwDrQR8jSogU9QicOBk1314ibVzicuYf8jThkRGHHhw2auib6GouZzyS1Lxw/132, createdBy=30ad2388091, createdName=夜以继日的梦想, createdTime=Sat Nov 02 00:00:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578939, encodeId=97355e8939b2, content=后来知道了吗?<span class="quote">lanseyouyu9004 2015-01-18 13:53:00 发表:<br>才四天Decision in Process 什么意思呢</span>, beContent=lanseyouyu9004 2015-01-18 13:53:00 发表: 才四天Decision in Process 什么意思呢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=721b2202035, createdName=120b8a49m20暂无昵称, createdTime=Sun Oct 27 00:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551041, encodeId=3167551041bf, content=没有pet的case也能在这发吗?<span class="quote">leijiang1031_43658003 2017-12-04 发表::<br>SCI(2016):4.563 临床核医学非常权威的杂志</span><span class="quote">leijiang1031_43658003 2017-12-04 09:45:00 发表:<br>临床核医学非常权威的杂志</span>, beContent=leijiang1031_43658003 2017-12-04 发表:: SCI(2016):4.563 临床核医学非常权威的杂志, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949d1402322, createdName=xyxiaochang, createdTime=Tue Jan 09 00:00:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549693, encodeId=238e549693c7, content=临床核医学非常权威的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=372, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75112214477, createdName=leijiang1031_43658003, createdTime=Mon Dec 04 09:45:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545120, encodeId=5a06545120b0, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:核医学领域算是比较老牌的杂志了吧,投Case还是比较容易的,但是CNM的论著还是很难投的;国内很多单位投CNM的case report都投烂了啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160620/IMG5767F7B4941608075.jpg, createdBy=16081612750, createdName=nnnuclear, createdTime=Fri Aug 04 16:55:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526419, encodeId=889752641923, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:1. 临床是其基础,办杂志的宗旨是影响/指导临床,基础研究的文章最好不要投了,99%拒绝。 <br> 2. CaseReport占很大比例,如果figure很impressive,或者是罕见病例,可以投。内容简练为主,不超过500字,临床大夫看的东西就应该精简,赞! <br> 3. 审稿快,一般不会超过一个月。 <br> 4. 楼上某位说错了,彩图第一张500刀,之后每张150刀。 <br> 5. 投四篇中一篇,25%命中率吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0aa1943518, createdName=邵小毛, createdTime=Sun Aug 28 11:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=509212, encodeId=9f5a50921228, content=审稿速度:1.0<br>经验分享:才四天Decision in Process 什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caed1611946, createdName=lanseyouyu9004, createdTime=Sun Jan 18 13:53:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2016-08-28 邵小毛

    审稿速度:2.0 | 投稿命中率:25.0
    经验分享:1. 临床是其基础,办杂志的宗旨是影响/指导临床,基础研究的文章最好不要投了,99%拒绝。
    2. CaseReport占很大比例,如果figure很impressive,或者是罕见病例,可以投。内容简练为主,不超过500字,临床大夫看的东西就应该精简,赞!
    3. 审稿快,一般不会超过一个月。
    4. 楼上某位说错了,彩图第一张500刀,之后每张150刀。
    5. 投四篇中一篇,25%命中率吧。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=902336, encodeId=bac2902336c6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床;核医学<br>经验分享:1. 更新下准确的影像因子,杂志官网可查到,2018年为6.709,2019为6.622。<br>2.老牌权威的核医学杂志。<br>3.近几年审稿速度比较快,一般不超过1个月,算审稿速度非常快的杂志了。<br>4.杂志的编辑很nice,但是很严谨。case report,只要图片和病例足够新颖,可以尝试,并不太难。论著有一定难度。<br>5.很临床的杂志,基础的文章不太收。<br>5.很多case report只在CNM发表,所以自引率比别的杂志高点可以理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rQvUN1zHBrywpiakiasoLOFr2w6FAZpJ4k6VRQsprf74lUTXZiavoSUjuLa18Igfbrx8amqbYTJXMVHbVtJOLq3vg/132, createdBy=8bbe1657894, createdName=丹子笑, createdTime=Thu Nov 26 00:17:50 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103324, encodeId=bc4e2103324c3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床研究<br>经验分享:Clin Nucl Med已经上升到和Eur J Nucl Med Mol Imaging、J Nucl Med一个分段的杂志了,但不可否认的是CNM论著的质量和后两者的差距还是比较大的,尤其是和JNM比,不过CNM主打case report,其实也还好了。<br>杂志侧重临床研究,前瞻性和回顾性均可,临床前研究,尤其是动物实验几乎秒拒。CNM文章审稿速度比EJNMMI和JNM慢,不过整体也还行,一审50天左右,修回一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Tue Nov 29 15:58:11 CST 2022, time=2022-11-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=960188, encodeId=d51896018886, content=这杂志20年if对半砍了???, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49f25135636, createdName=14665fa9m69暂无昵称, createdTime=Sun Apr 25 08:05:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579239, encodeId=b2e65e9239ca, content=现在自引率这么高了吗<span class="quote">173****0520暂无昵称 2019-10-27 发表::<br>后来知道了吗?</span><span class="quote">173****0520暂无昵称 2019-10-27 00:00:00 发表:<br>后来知道了吗?</span>, beContent=173****0520暂无昵称 2019-10-27 发表:: 后来知道了吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqKeFVU0XGMYxKONpLlkGRwDrQR8jSogU9QicOBk1314ibVzicuYf8jThkRGHHhw2auib6GouZzyS1Lxw/132, createdBy=30ad2388091, createdName=夜以继日的梦想, createdTime=Sat Nov 02 00:00:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578939, encodeId=97355e8939b2, content=后来知道了吗?<span class="quote">lanseyouyu9004 2015-01-18 13:53:00 发表:<br>才四天Decision in Process 什么意思呢</span>, beContent=lanseyouyu9004 2015-01-18 13:53:00 发表: 才四天Decision in Process 什么意思呢, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=721b2202035, createdName=120b8a49m20暂无昵称, createdTime=Sun Oct 27 00:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551041, encodeId=3167551041bf, content=没有pet的case也能在这发吗?<span class="quote">leijiang1031_43658003 2017-12-04 发表::<br>SCI(2016):4.563 临床核医学非常权威的杂志</span><span class="quote">leijiang1031_43658003 2017-12-04 09:45:00 发表:<br>临床核医学非常权威的杂志</span>, beContent=leijiang1031_43658003 2017-12-04 发表:: SCI(2016):4.563 临床核医学非常权威的杂志, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949d1402322, createdName=xyxiaochang, createdTime=Tue Jan 09 00:00:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549693, encodeId=238e549693c7, content=临床核医学非常权威的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=372, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75112214477, createdName=leijiang1031_43658003, createdTime=Mon Dec 04 09:45:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545120, encodeId=5a06545120b0, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:核医学领域算是比较老牌的杂志了吧,投Case还是比较容易的,但是CNM的论著还是很难投的;国内很多单位投CNM的case report都投烂了啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160620/IMG5767F7B4941608075.jpg, createdBy=16081612750, createdName=nnnuclear, createdTime=Fri Aug 04 16:55:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526419, encodeId=889752641923, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:1. 临床是其基础,办杂志的宗旨是影响/指导临床,基础研究的文章最好不要投了,99%拒绝。 <br> 2. CaseReport占很大比例,如果figure很impressive,或者是罕见病例,可以投。内容简练为主,不超过500字,临床大夫看的东西就应该精简,赞! <br> 3. 审稿快,一般不会超过一个月。 <br> 4. 楼上某位说错了,彩图第一张500刀,之后每张150刀。 <br> 5. 投四篇中一篇,25%命中率吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0aa1943518, createdName=邵小毛, createdTime=Sun Aug 28 11:03:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=509212, encodeId=9f5a50921228, content=审稿速度:1.0<br>经验分享:才四天Decision in Process 什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caed1611946, createdName=lanseyouyu9004, createdTime=Sun Jan 18 13:53:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2015-01-18 lanseyouyu9004

    审稿速度:1.0
    经验分享:才四天Decision in Process 什么意思呢

    0

共23条页码: 1/3页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分